CN107353282A - 从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 - Google Patents
从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 Download PDFInfo
- Publication number
- CN107353282A CN107353282A CN201710504780.7A CN201710504780A CN107353282A CN 107353282 A CN107353282 A CN 107353282A CN 201710504780 A CN201710504780 A CN 201710504780A CN 107353282 A CN107353282 A CN 107353282A
- Authority
- CN
- China
- Prior art keywords
- puerarin
- root
- water
- bed
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 29
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 244000046146 Pueraria lobata Species 0.000 title claims abstract description 26
- 235000010575 Pueraria lobata Nutrition 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 49
- 239000000284 extract Substances 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 238000011084 recovery Methods 0.000 claims abstract description 10
- 235000007240 daidzein Nutrition 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000000243 solution Substances 0.000 claims description 18
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 239000003480 eluent Substances 0.000 claims description 12
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims description 12
- 230000009471 action Effects 0.000 claims description 11
- 238000010828 elution Methods 0.000 claims description 11
- 229940045109 genistein Drugs 0.000 claims description 11
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims description 11
- 235000006539 genistein Nutrition 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 229930003944 flavone Natural products 0.000 claims description 8
- 150000002212 flavone derivatives Chemical class 0.000 claims description 8
- 235000011949 flavones Nutrition 0.000 claims description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 6
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 6
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 6
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000001179 sorption measurement Methods 0.000 claims description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 239000003961 penetration enhancing agent Substances 0.000 claims description 4
- 240000005528 Arctium lappa Species 0.000 claims description 3
- 235000003130 Arctium lappa Nutrition 0.000 claims description 3
- 235000008078 Arctium minus Nutrition 0.000 claims description 3
- 244000025254 Cannabis sativa Species 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 244000247747 Coptis groenlandica Species 0.000 claims description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 244000194101 Ginkgo biloba Species 0.000 claims description 3
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 3
- 241000234435 Lilium Species 0.000 claims description 3
- 240000003915 Lophatherum gracile Species 0.000 claims description 3
- 244000241838 Lycium barbarum Species 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 240000000249 Morus alba Species 0.000 claims description 3
- 235000008708 Morus alba Nutrition 0.000 claims description 3
- 240000002948 Ophiopogon intermedius Species 0.000 claims description 3
- 244000197580 Poria cocos Species 0.000 claims description 3
- 235000008599 Poria cocos Nutrition 0.000 claims description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 3
- 239000012895 dilution Substances 0.000 claims description 3
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000003623 enhancer Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 3
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229920000344 molecularly imprinted polymer Polymers 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229960003080 taurine Drugs 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 240000002853 Nelumbo nucifera Species 0.000 claims 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000010630 cinnamon oil Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 8
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract description 3
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 229960000458 allantoin Drugs 0.000 abstract description 3
- 241001295925 Gegenes Species 0.000 abstract description 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 2
- 238000002386 leaching Methods 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 230000008020 evaporation Effects 0.000 abstract 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 4
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 4
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 244000077995 Coix lacryma jobi Species 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000219780 Pueraria Species 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 240000006859 Jasminum officinale Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- MGJLSBDCWOSMHL-WFMNFSIZSA-N Ononin Natural products O(C)c1ccc(C=2C(=O)c3c(OC=2)cc(O[C@H]2[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O2)cc3)cc1 MGJLSBDCWOSMHL-WFMNFSIZSA-N 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- ZHKVKULEJZXSLW-KZZGZOJNSA-N beta-daucosterol Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(O)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ZHKVKULEJZXSLW-KZZGZOJNSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- PJWPOUFMMWFJOL-UHFFFAOYSA-N beta-sitosterol-beta-D-glucoside Natural products CCC(CCC(C)C1CCC2C3C=CC4CC(CCC4(C)C3CCC12C)OC5OC(CO)C(O)C(O)C5O)C(C)C PJWPOUFMMWFJOL-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000004223 monosodium glutamate Substances 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- MGJLSBDCWOSMHL-MIUGBVLSSA-N ononin Chemical compound C1=CC(OC)=CC=C1C1=COC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-MIUGBVLSSA-N 0.000 description 1
- MGJLSBDCWOSMHL-UHFFFAOYSA-N ononoside Natural products C1=CC(OC)=CC=C1C1=COC2=CC(OC3C(C(O)C(O)C(CO)O3)O)=CC=C2C1=O MGJLSBDCWOSMHL-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/198—Dry unshaped finely divided cereal products, not provided for in groups A23L7/117 - A23L7/196 and A23L29/00, e.g. meal, flour, powder, dried cereal creams or extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
- C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/40—Separation, e.g. from natural material; Purification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中药提取技术领域,具体地说是从野葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺,包括酒精超声波浸提、药液回收、蒸发浓缩成膏状、对浸膏溶解萃取、以及分别采取三步萃取分离有效组分大豆苷元、尿囊素、葛根素。本发明对葛根中大部分有效成分都分离提纯加以利用,大大提高了葛根的综合利用价值。特别值得一提的是,本发明从葛根素中分离了不可利用的剧毒成分3'氰基葛根素,其收率3.22%(含量98.1%),同时还提供了葛根复方制剂。
Description
技术领域
本发明属于中药有效成分生物提取技术领域,具体的说涉及从野葛根中提取有效成分葛根素技术。
技术背景
葛根素是近十年来年世界各国广泛研究和发展的专供医药工业用于攻克心脑血管、各种癌症、眼科杂顽症的生物原料药。该产品具有所有化学药品不可替代的多种优点:1、生物药理有效成份多样化,主要成份具有防止血管通透性异常升高。迅速抑制病灶细胞和血小板凝集,增加血中氧含量和氧饱和度,改善微循环和促进血管生成使裂壁得到修复等作用。对闭塞性心脑血管病,中心性视网膜炎、动脉硬化、冠心病、梗塞前综合症、血栓性静脉炎等可以达到多重效果。2、对动物性神经行为很安全。葛根素针剂、片剂作用方式主要是通络、活血化瘀、降低梗塞动物的血浆内皮素含量,提高血清SOD含量,增强肌体的免疫功能,无负作用。3、肌体不易产生抗药性。中草药往往含有数种成份,且作用机理与一般化学药品截然不同。如:日本从黄豆中提取葛根素针剂治疗心脑血管病,经过数年的临床实践,康复率达98%以上,同时,未发现任何不良反应及副作用。4、对环境安全,没有毒废物残留。中草药制剂含有的化学成份是自然畀中具有的天然生理结构,在自然生态中必然存在降解它的物质基因。因此,在生产过程中无任何累废积物链和残毒之虑。
日本从黄豆中提取葛根素系列产品,但成本较高,主要因素是原料较贵。国内报道的葛根素提取工艺较复杂,手段落后,收率较低,并对副产品无利用,经过实践证明不成功。
本申请人在先申请(专利200910022619.1)虽然克服了现有葛根有效成分提取中一些问题,但是对于葛根中有些成分提取不够充分。由于葛根中提取的葛根黄酮类化合物具有抗氧化、抗肿瘤、防治心脑血管病等药理作用,近几年对葛根医药利用更得到重视,因此,葛根黄酮的分离成为最为紧迫的需要。
另外,葛根制剂在肠道吸收和透皮制剂中存在吸收率太低,药效难以发挥的缺陷。
发明内容
本发明目的是提供一种从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺,以提高葛根的综合利用价值。
从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺,其特征是按照以下步骤实施:
(1)葛根黄酮提取:称取野葛根加适量水润透,加80%乙醇超声提取2次,乙醇质量分数不低于60.0%、提取时间不低于138.0min、液固比至少11.3mL/g、提取温度70.0℃以下,过滤,合并滤液,70'C以下减压干燥,得黄褐色粉末;
(2)葛根素和大豆苷元分离:将黄色粉末加入适量湖景成水提取液,将提取液流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的75%乙醇进行洗脱操作,收集洗脱液,浓缩回收乙醇;往浓缩液中加HCl至HCl浓度为2mRl/L,并在90℃水浴条件下酸解60min;酸解液趁热过滤,往滤液中加5倍体积水稀释后流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的50%乙醇进行洗脱操作,收集洗脱液,并浓缩回收乙醇;浓缩液在4℃条件下贮存24h,收集沉淀得到葛根素;用4倍柱床体积的95%乙醇对树脂柱进行洗脱操作,收集洗脱液,并浓缩回收乙醇;往浓缩液中加入等体积的水,在4℃条件下贮存24h,收集沉淀得到大豆苷元;
(3)染料木素分离:a)以染料木素分子印迹聚合物微粒为填料制成固相萃取柱;b)对步骤a制备的固相萃取柱进行活化、上样,然后依次用体积比49-51%水的步骤(2)提取液加入乙腈的溶液、体积比4.9-5.1%水的乙腈溶液对萃取柱进行淋洗,最后用体积比0.18-0.22%TEA的甲醇溶液洗脱;洗脱液蒸干得染料木素。
步骤(1)所得葛根黄酮与黄芩、黄连、甘草四味药物按10-12∶1-2∶1-2∶0.5-1的重量比混合,提取物加入辅料,用于制备治疗腹泻的口服制剂。
步骤(2)中葛根素与牛磺酸制成复方口服制剂用于降低血糖,并且加入占总组分0.5-1%的壳聚糖做肠道吸收促进剂。
步骤(2)中葛根素与与银杏叶提取物配伍用于制备抗衰老外用制剂,并且加入肉桂油和丁香油做作为透皮吸收促进剂。
步骤(1)所得粉末混入山药、茯苓、淡竹叶、薏苡仁、桑椹、百合中的一种或多种后与山药、枸杞、麦冬草、牛蒡子组合制成降血糖和血脂的的保健食品。
本发明采用野葛根提取葛根素,将危害和严重影响林木健康生长的野葛藤蔓变害为宝,工艺中的浸取温度合理,使得葛根素收率较高,生产安全,对设备要求较低,同时尾气得到回收,废碴被制成复合饲料,降低了综合成本。同时,本发明对葛根中大部分有效成分都分离提纯加以利用,大大提高了葛根的综合利用价值。特别值得一提的是,
本发明从葛根素中分离了不可利用的剧毒成分3'氰基葛根素,但该成分在国防建设中却起着工业味精的作用,其收率3.22%(含量98.1%),本发明提取了葛根素,大豆苷元,大豆苷,染料木素,β-胡萝卜苷和芒柄花苷等现有工艺无法分离的成分,大大提高了葛根药用价值的发挥。
本发明工艺可以提取的葛根中有效成分包括:
大豆苷元组分中:①、大豆苷元收率0.58%(含量98.g%);②、大豆苷收率0.49%(含量99.2%);③、染料木苷收率0.46%(含量99.5%);④、葡萄糖大豆苷收率0.25%(含量99.8g%)
尿囊素组分:①、尿囊素牧率0.62%(含量98.87%);②、胡萝卜素收率0.53%(含量99.8%);③、染料木素收率0.47%(含量95.5g%);④、8.碳一芹糖收率0.42%(含量93.3%);⑤、谷甾醇收率0.288%(含量97.9%)。
葛根素组分:①、葛根素收率6.8%(含量99.8%);②、3 7-氰基葛根素收率3.22%(含量98.1%);③、芒柄素收率2.56%(含量98.89%);④、大豆素收率2.5%(含量98%)。
特别是本发明提供的葛根复方制剂采用了肠道促进吸收剂和透皮吸收促进剂,有助于大大提高吸收率并提高功效。
具体实施方式
(1)葛根黄酮提取:称取野葛根加适量水润透,加80%乙醇超声提取2次,乙醇质量分数不低于60.0%、提取时间不低于138.0min、液固比至少11.3mL/g、提取温度70.0℃以上,过滤,合并滤液,70'C以下减压千燥,得黄褐色粉末;
(2)葛根素和大豆苷元分离:将黄色粉末加入适量湖景成水提取液,将提取液流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的75%乙醇进行洗脱操作,收集洗脱液,浓缩回收乙醇;往浓缩液中加HCl至HCl浓度为2mRl/L,并在90℃水浴条件下酸解60min;酸解液趁热过滤,往滤液中加5倍体积水稀释后流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的50%乙醇进行洗脱操作,收集洗脱液,并浓缩回收乙醇;浓缩液在4℃条件下贮存24h,收集沉淀得到葛根素;用4倍柱床体积的95%乙醇对树脂柱进行洗脱操作,收集洗脱液,并浓缩回收乙醇;往浓缩液中加入等体积的水,在4℃条件下贮存24h,收集沉淀得到大豆苷元;
(3)染料木素分离:a)以染料木素分子印迹聚合物微粒为填料制成固相萃取柱;b)对步骤a制备的固相萃取柱进行活化、上样,然后依次用体积比49-51%水的步骤(2)提取液加入乙腈的溶液、体积比4.9-5.1%水的乙腈溶液对萃取柱进行淋洗,最后用体积比0.18-0.22%TEA的甲醇溶液洗脱;洗脱液蒸干得染料木素。
步骤(1)所得葛根黄酮与黄芩、黄连、甘草四味药物按10-12∶1-2∶1-2∶0.5-1的重量比混合,提取物加入辅料,用于制备治疗腹泻的口服制剂。
步骤(2)中葛根素与牛磺酸制成复方口服制剂用于降低血糖,并且加入占总组分0.5-1%的壳聚糖做肠道吸收促进剂。
步骤(2)中葛根素与与银杏叶提取物配伍用于制备抗衰老外用制剂,并且加入肉桂油和丁香油做作为透皮吸收促进剂。
步骤(1)所得粉末混入山药、茯苓、淡竹叶、薏苡仁、桑椹、百合中的一种或多种后与山药、枸杞、麦冬草、牛蒡子组合制成降血糖和血脂的的保健食品。
Claims (5)
1.从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺,其特征是按照以下步骤实施:
(1)葛根黄酮提取:称取野葛根加适量水润透,加80%乙醇超声提取2次,乙醇质量分数不低于60%、提取时间不低于138.0min、液固比至少11.3mL/g、提取温度70℃以下,过滤、合并滤液,70℃以下减压干燥,得黄褐色粉末;
(2)葛根素和大豆苷元分离:将黄色粉末加入适量湖景成水提取液,将提取液流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的75%乙醇进行洗脱操作,收集洗脱液,浓缩回收乙醇;往浓缩液中加HCl至HCl浓度为2mRl/L,并在90℃水浴条件下酸解60min;酸解液趁热过滤,往滤液中加5倍体积水稀释后流过H103大孔树脂床,进行吸附操作;用4倍柱床体积水清洗树脂床,然后用4倍柱床体积的50%乙醇进行洗脱操作,收集洗脱液,并浓缩回收乙醇;浓缩液在4℃条件下贮存24h,收集沉淀得到葛根素;用4倍柱床体积的95%乙醇对树脂柱进行洗脱操作,收集洗脱液,并浓缩回收乙醇;往浓缩液中加入等量体积的水,在4℃条件下贮存24h,收集沉淀得到大豆苷元;
(3)染料木素分离:a)以染料木素分子印迹聚合物微粒为填料制成固相萃取柱;b)对步骤a制备的固相萃取柱进行活化、上样,然后依次用体积比49-51%水的步骤(2)提取液加入乙腈的溶液、体积比4.9-5.1%水的乙腈溶液对萃取柱进行淋洗,最后用体积比0.18-0.22%TEA的甲醇溶液洗脱;洗脱液蒸干得染料木素。
2.根据权利要求1所述的工艺,其特征是步骤(1)所得葛根黄酮与黄芩、黄连、甘草四味药物按10-12∶1-2∶1-2∶0.5-1的重量比混合,提取物加入辅料,用于制备治疗腹泻的口服制剂。
3.根据权利要求1所述的工艺,其特征是步骤(2)中葛根素与牛磺酸制成复方口服制剂用于降低血糖,并且加入占总组分0.5-1%的壳聚糖做肠道吸收促进剂。
4.根据权利要求1所述的工艺,其特征是步骤(2)中葛根素与与银杏叶提取物配伍用于制备抗衰老外用制剂,并且加入肉桂油和丁香油做作为透皮吸收促进剂。
5.根据权利要求1所述的工艺,其特征是步骤(1)所得粉末混入山药、茯苓、淡竹叶、薏苡仁、桑椹、百合中的一种或多种后与山药、枸杞、麦冬草、牛蒡子组合制成降血糖和血脂的的保健食品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710504780.7A CN107353282A (zh) | 2017-06-28 | 2017-06-28 | 从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710504780.7A CN107353282A (zh) | 2017-06-28 | 2017-06-28 | 从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107353282A true CN107353282A (zh) | 2017-11-17 |
Family
ID=60273150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710504780.7A Pending CN107353282A (zh) | 2017-06-28 | 2017-06-28 | 从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107353282A (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1476882A (zh) * | 2003-07-25 | 2004-02-25 | 广西壮族自治区人民医院 | 一种具有降糖功效的药物及其制备方法 |
CN101210004A (zh) * | 2006-12-27 | 2008-07-02 | 中国科学院大连化学物理研究所 | 一种对葛根粗提物中染料木素选择性的富集分离方法 |
CN101278991A (zh) * | 2008-05-22 | 2008-10-08 | 南方医科大学 | 一种葛根芩连药物的有效成分的检测方法 |
CN103211729A (zh) * | 2013-04-16 | 2013-07-24 | 天津科丝美特生物科技有限公司 | 一种具有抗衰老作用的护肤组合物 |
CN104189453A (zh) * | 2014-09-01 | 2014-12-10 | 陶叶 | 一种降血糖血脂的葛根制剂及其制备方法 |
CN105218533A (zh) * | 2015-10-13 | 2016-01-06 | 江西农业大学 | 一种从葛根中同时分离纯化葛根素和大豆苷元的方法 |
-
2017
- 2017-06-28 CN CN201710504780.7A patent/CN107353282A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1476882A (zh) * | 2003-07-25 | 2004-02-25 | 广西壮族自治区人民医院 | 一种具有降糖功效的药物及其制备方法 |
CN101210004A (zh) * | 2006-12-27 | 2008-07-02 | 中国科学院大连化学物理研究所 | 一种对葛根粗提物中染料木素选择性的富集分离方法 |
CN101278991A (zh) * | 2008-05-22 | 2008-10-08 | 南方医科大学 | 一种葛根芩连药物的有效成分的检测方法 |
CN103211729A (zh) * | 2013-04-16 | 2013-07-24 | 天津科丝美特生物科技有限公司 | 一种具有抗衰老作用的护肤组合物 |
CN104189453A (zh) * | 2014-09-01 | 2014-12-10 | 陶叶 | 一种降血糖血脂的葛根制剂及其制备方法 |
CN105218533A (zh) * | 2015-10-13 | 2016-01-06 | 江西农业大学 | 一种从葛根中同时分离纯化葛根素和大豆苷元的方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101560201B (zh) | 从葛根中萃取葛根素及多种医药成分的工艺 | |
CN101456918B (zh) | 黄精多糖及其制备方法以及黄精多糖在制备降血糖、降血脂药物中的应用 | |
CN101585885A (zh) | 一种玉竹多糖的制备方法 | |
CN101416990A (zh) | 茉莉花提取物及其制备方法和用途 | |
CN104667021A (zh) | 一种含竹叶黄酮的复方制品及其制备方法 | |
CN102994350A (zh) | 一种具有降血脂功能苦荞酒的制备方法 | |
CN101463025A (zh) | 一种山楂叶总黄酮的提取制备方法 | |
CN107303303B (zh) | 制备东革阿里有效成分及组合应用 | |
CN102771593A (zh) | 一种降血糖、血脂、血压的藤茶制剂及其制备方法 | |
CN103224491A (zh) | 以水为溶媒提取高纯葛根素的方法 | |
CN106511406B (zh) | 一种银杏叶提取物的制备方法 | |
CN102872195B (zh) | 一种肉桂总多酚提取物的制备方法及其应用 | |
CN105017442B (zh) | 人参多糖的提取方法 | |
CN104306519B (zh) | 一种抗氧化的复合中药提取分离物及其制备方法 | |
CN104398619B (zh) | 鸡矢藤提取物及其用途 | |
CN103372034A (zh) | 银杏叶提取物的制备方法 | |
CN107353282A (zh) | 从葛根中萃取高纯度葛根素及多种珍稀医药成分的工艺 | |
CN113072650B (zh) | 一种野菠萝多糖的制备方法 | |
CN107982310A (zh) | 复方葛根黄酮制剂的制备方法 | |
CN106361811B (zh) | 一种通脉药物组合物及其制备方法 | |
CN106581236A (zh) | 一种促进胃动力的药物组合物及其制备方法和应用 | |
CN106727797A (zh) | 一种提取刺五加的方法 | |
CN101623312A (zh) | 一种连续提取藏木香中有效物质的方法 | |
CN101647858B (zh) | 一种丹参水溶性提取物的制备方法 | |
CN111670985A (zh) | 一种含水溶性大麻二酚保健茶的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171117 |
|
RJ01 | Rejection of invention patent application after publication |